McKesson Co. (NYSE:MCK) Receives Consensus Recommendation of “Hold” from Analysts
Shares of McKesson Co. (NYSE:MCK) have been assigned an average recommendation of “Hold” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $146.22.
MCK has been the topic of a number of research reports. ValuEngine lowered shares of Valero Energy from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research report on Monday, July 22nd. They set a “buy” rating and a $47.00 price target on the stock. Zacks Investment Research lowered shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Wolfe Research initiated coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Finally, Credit Suisse Group raised shares of StoneCo from a “neutral” rating to an “outperform” rating in a research report on Monday, July 22nd.
MCK traded up $0.98 during trading on Thursday, reaching $142.26. The company’s stock had a trading volume of 17,176 shares, compared to its average volume of 1,086,137. The company has a current ratio of 1.02, a quick ratio of 0.58 and a debt-to-equity ratio of 0.88. The stock has a fifty day simple moving average of $137.15. McKesson has a 1 year low of $106.11 and a 1 year high of $148.23. The company has a market capitalization of $25.90 billion, a P/E ratio of 10.48, a price-to-earnings-growth ratio of 1.42 and a beta of 1.11.
In other news, EVP Lori A. Schechter sold 2,766 shares of McKesson stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $133.59, for a total transaction of $369,509.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Britt J. Vitalone sold 832 shares of McKesson stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $129.17, for a total transaction of $107,469.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,174 shares of company stock worth $804,583. Corporate insiders own 0.88% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Gradient Investments LLC raised its position in McKesson by 1,944.4% in the second quarter. Gradient Investments LLC now owns 184 shares of the company’s stock valued at $25,000 after purchasing an additional 175 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in McKesson in the first quarter valued at approximately $27,000. Smart Portfolios LLC purchased a new stake in McKesson in the first quarter valued at approximately $35,000. Investors Research Corp purchased a new stake in McKesson in the first quarter valued at approximately $36,000. Finally, Berman Capital Advisors LLC raised its position in McKesson by 175.2% in the second quarter. Berman Capital Advisors LLC now owns 289 shares of the company’s stock valued at $37,000 after purchasing an additional 184 shares during the period. 88.92% of the stock is currently owned by institutional investors.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Read More: Liquidity
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.